[{"orgOrder":0,"company":"Thryv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dofetilide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Thryv Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Thryv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Thryv Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Dofetilide

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : LQT-1213 is a novel, first-in-class SGK1 inhibitor that the USFDA granted Orphan Drug Designation for the treatment of Long QT Syndrome.

                          Brand Name : LQT-1213

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 01, 2024

                          Lead Product(s) : Islasertib,Dofetilide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank